Acadia Pharmaceuticals
ACAD
246 hedge funds and large institutions have $2.13B invested in Acadia Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 69 increasing their positions, 88 reducing their positions, and 47 closing their positions.
45% more call options, than puts
Call options by funds: $25.3M | Put options by funds: $17.4M
2.23% more ownership
Funds ownership: 91.23% → 93.46% (+2.2%)
6% less funds holding
Funds holding: 263 → 246 (-17)
22% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 88
23% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 47
40% less capital invested
Capital invested by funds: $3.56B → $2.13B (-$1.44B)
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$78.8M |
| 2 |
Morgan Stanley
New York
|
+$40.7M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$32.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$28.7M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$55.1M |
| 2 |
Janus Henderson Group
London,
|
-$42.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$20.2M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$17M |
| 5 |
TP
Thunderbird Partners
London,
United Kingdom
|
-$16.8M |
ACAD Hedge Fund Activity: Q2 2022 in Review
246 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2022, worth a combined $2.13B — down 40% from $3.56B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of ACAD and 36 opened new positions — a net loss of 11 holders — while 88 trimmed existing stakes and 69 added.
The largest buyer was RTW Investments, opening a new position worth an estimated $78.8M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $55.1M sold.
- 246 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2022, down from 263 in Q1 2022.
- Funds reported $2.13B of Acadia Pharmaceuticals stock for Q2 2022, down 40% quarter-over-quarter.
- 36 funds opened new Acadia Pharmaceuticals positions in Q2 2022 and 47 closed out, a net change of -11 holders.
- The largest Acadia Pharmaceuticals buyer in Q2 2022 was RTW Investments, an estimated $78.8M added.
- The largest Acadia Pharmaceuticals seller in Q2 2022 was Avoro Capital Advisors, an estimated $55.1M sold.
Based on aggregated 13F filings for Q2 2022.